PYC Therapeutics is a clinical-stage biotechnology company that has advanced its drug candidate, VP-001, for the treatment of Retinitis Pigmentosa type 11 (RP11) into human trials.
The US Food and Drug Administration (FDA) has cleared PYC's Investigational New Drug (IND) application for VP-001 and the company plans to begin dosing RP11 patients with this drug candidate in 2Q 2023.
VP-001 is a precision therapy that aims to restore the expression of the PRPF31 gene, which is insufficiently expressed in people with RP11, back to levels required for the normal function of the retina.
There are currently no treatment options available for RP11, which represents an estimated >$1 billion p.a. addressable market.